MétaCan
Menu
Back to cohort
Record W2331287588 · doi:10.1158/1538-7445.am2012-2899

Abstract 2899: Doxorubicin-mitomycin co-loaded polymer lipid nanoparticle enhanced efficacy against breast tumor and decreased toxicity as compared to Doxil

2012· article· en· W2331287588 on OpenAlexaff
Preethy Prasad, Adam J. Shuhendler, Ping Cai, Mei Sun, Peter Liu, Rob Bistrow, Andrew M. Rauth, Xiao Yu Wu

Bibliographic record

VenueCancer Research · 2012
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Lipids, and Metabolism
Canadian institutionsToronto General HospitalPrincess Margaret Cancer CentreHeart and Stroke FoundationUniversity Health NetworkUniversity of Toronto
Fundersnot available
KeywordsToxicityMedicineDoxorubicinCancerIn vivoChemotherapyBreast cancerMitomycin CPharmacologyInternal medicineSurgeryBiology

Abstract

fetched live from OpenAlex

Abstract Background: Multidrug resistance acquired by cancer cells and the dose-limiting toxicity of anti-cancer drugs are contributing factors to the failure of cancer chemotherapy. Doxorubicin (Dox) -Mitomycin C (MMC) co-loaded stealth polymer lipid hybrid nanoparticles (DMsPLN) was developed to overcome these problems and demonstrated anti-cancer synergy in vitro. The purpose of the study is to evaluate in vivo efficacy and safety of DMsPLN in a breast cancer model. Method: The efficacy and systemic toxicity of DMsPLN were evaluated against clinically used Doxil in mice bearing murine or human mammary carcinomas. DMsPLN were administered intravenously at 50 mg/m2 doxorubicin single dose or once every 4 days for 4 cycles. Tumor size was measured as function of time to determine therapeutic efficacy of the treatment and systemic toxicity was monitored by repeated measurement of body weight. Results: Significant difference in the efficacy of DMsPLN relative to Doxil was observed in both sensitive and resistant tumor models. A clear enhancement of tumor growth delay (TLD) was evident with both single and 4 times doses of DMs PLN. In single dose and 4x dose DMsPLN groups, the TGD were significantly improved to 100% and 300% in the sensitive tumor model. In the resistant tumor model, the TGD ranged from 30%-130% for the single dose and the 4x dose DMsPLN, respectively. 10% of the mice showed complete tumor disappearance in DMs PLN and 25% complete tumor disappearance was observed in DMs PLN 4x group in the sensitive tumor model. 11% of the mice showed complete tumor disappearance in both DMs PLN and in DMs PLN 4x group in the resistant tumor model. In addition to enhanced efficacy, none of the toxicity associated with Doxil treatment were observed in single or 4x DMsPLN treatment. Conclusions: DMsPLN demonstrated enhanced efficacy and reduced toxicity over Doxil in aggressive mouse models of sensitive and resistant breast cancers. Therefore, DMsPLN may provide clinically relevant, more aggressive anti-cancer interventions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2899. doi:1538-7445.AM2012-2899

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.362
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer, Lipids, and MetabolismFrench-language works237,207